Keyphrases
B Cell Subtypes
14%
BCL6
42%
CD10
42%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Event-free Survival
14%
Germinal Center B Cells
28%
Hans Algorithm
100%
Indonesian
100%
Jakarta
14%
Ki-67
28%
Lymphoma Patients
100%
MUM1
100%
Non-germinal Centre
14%
Optimal Tradeoff
14%
Prognosis Prediction
100%
Prognostic Value
14%
Prognosticate
14%
Protein Expression
14%
Protein Level
14%
R-CHOP
100%
R-CHOP Therapy
28%
Receiver Operating Characteristic Curve
14%
Retrospective Cohort Study
14%
Single Marker
14%
Survival Analysis
14%
Survival Disparities
14%
Treatment Response
14%
INIS
algorithms
100%
auc
33%
b centers
33%
comparative evaluations
16%
curves
16%
hospitals
16%
levels
16%
lymphomas
100%
patients
100%
proteins
50%
sensitivity
16%
specificity
16%
therapy
33%
values
50%
Medicine and Dentistry
B Cell
40%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Diffuse Large B-Cell Lymphoma
100%
Event Free Survival
20%
Germinal Center
40%
Interferon Regulatory Factor 4
20%
Protein Expression
20%
Retrospective Cohort Study
20%
Sensitivity and Specificity
20%
Survival Analysis
20%
Treatment Response
20%
Immunology and Microbiology
B Cell
100%
BCL6
42%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Event Free Survival
14%
Germinal Center
28%
Interferon Regulatory Factor 4
14%
Protein Expression
14%
Neuroscience
B Cell
100%
BCL6
42%
CHOP
100%
Germinal Center
28%
IRF4
14%
Protein Expression
14%
Survival Analysis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Diffuse Large B Cell Lymphoma
100%
Event Free Survival
20%
Interferon Regulatory Factor 4
20%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
BCL6
42%
Cohort Study
14%
Event Free Survival
14%
IRF4
14%
Protein Expression
14%